These improvements may prove critical for women with PCOS should GLP-1 medications obtain the appropriate authorisation, as managing weight and insulin resistance can significantly improve overall health and fertility
Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
BY REGION The GLP-1 agonists market covers North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i): Renal Implications
For safe, science-backed weight loss, your best bet is to work with a licensed provider who can prescribe real GLP-1 treatments